Hepatocellular carcinoma (HCC) is a difficult-to-treat cancer related to inflammation, and previous studies showed that flavonoids like EGCG and fisetin can inhibit tumor-promoting signals.
A transcriptome analysis using RNA-seq on HEP3B cells revealed that both EGCG and fisetin significantly altered the expression of a large number of genes when the cells were stimulated to mimic the tumor microenvironment.
The findings point to shared mechanisms involving cancer-related processes such as ECM dynamics, angiogenesis, and inflammation, suggesting potential new approaches for using these nutraceuticals in HCC prevention and treatment.
Modified purine derivatives, specifically pyrazolopyrimidines, have been identified as selective inhibitors of angiogenic receptor tyrosine kinases, impacting endothelial cell functions crucial for blood vessel growth.
Four synthesized compounds showed potential in inhibiting endothelial cell proliferation, migration, and differentiation, both naturally and when stimulated by Vascular Endothelial Growth Factor (VEGF), while also suppressing key signaling pathways.
In mice, effective compounds slowed the growth of lung cancer transplants and reduced blood vessel formation in tumors without toxic effects, with one derivative notably influencing gene expression related to cell division and cholesterol biosynthesis.